Carcinomatosis — Trials

Carcinomatosis — Trials · CancerIndex

Clinical trials

Registered studies

221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 74
Recruiting: 42
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: Guangzhou Medical University
Termination share: 26%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04315246	177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)	withdrawn	Phase 1 / Phase 2	0	Y-mAbs TherapeuticsINDUSTRY	2	Jul 15, 2022	clinicaltrials
NCT01095523	Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases	withdrawn	Phase 2	0	National Cancer Institute (NCI)NIH	1	Jul 2, 2017